Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $16.69, for a total value of $917,950.00. Following the sale, the chief executive officer now directly owns 276,017 shares of the company’s stock, valued at $4,606,723.73. This trade represents a 16.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total value of $876,150.00.
• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total value of $867,350.00.

Centessa Pharmaceuticals Stock Down 3.3 %

Centessa Pharmaceuticals stock opened at $15.75 on Friday. The stock has a market capitalization of $2.08 billion, a PE ratio of -10.29 and a beta of 1.54. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09. The business has a 50 day simple moving average of $16.47 and a 200-day simple moving average of $16.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Analysts Set New Price Targets

Several brokerages recently weighed in on CNTA. Morgan Stanley reiterated an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $26.00.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock valued at $959,000 after buying an additional 660 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after buying an additional 865 shares in the last quarter. Atria Investments Inc increased its position in shares of Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after buying an additional 1,116 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $31,000. Finally, Barclays PLC boosted its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.